Loading...
Promoter choice: Who should drive the CAR in T cells?
Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for B cell malignancies, with emerging potential for the treatment of other hematologic cancers and solid tumors. The strength of the promoter within the CAR cassette will alter CAR-polypeptide levels on the cell surface of the...
Saved in:
| Published in: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Public Library of Science
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7380635/ https://ncbi.nlm.nih.gov/pubmed/32706785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0232915 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|